Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 166 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Type 2 - Insulin-Treated Clear all
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044395
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Mesa, Arizona • Irvine, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Not applicable Interventional

Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED

NCT06899191
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Hyperglycemia, Insulin Dependent Diabetes
Interventions
Hemoglobin A1c, Observation Unit
Diagnostic Test · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Active, not recruiting No phase listed Observational

The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System

NCT05754281
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
2nd Gen LabPatch Glucose Sensing System
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes, Diabetes, Autoimmune, Diabetes Mellitus, Diabetes Mellitus Type 2, Diabetes Mellitus, Type I, Diabetes, Type II, Diabetes, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus Type II, Diabetes Type 2 on Insulin
Interventions
Bionic Pancreas, Routine Care
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

NCT00065312
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
naveglitazar
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 16, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The CARING Study: Creating and Restoring Health Through Nutrition Guidance

NCT05795439
View directory record Official record
Conditions
Type2diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Low-fat, vegan diet
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes

NCT02060916
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
PAZ320
Drug
Lead sponsor
Boston Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Jefferson, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 3 Interventional

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

NCT00135941
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
insulin glargine, insulin glulisine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

NCT01451398
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin, Technosphere Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
50
States / cities
Anaheim, California • Huntington Beach, California • Laguna Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT01011868
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 16, 2026, 10:14 PM EDT
Withdrawn Not applicable Interventional

Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

NCT04227626
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
GlucoSTAT
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 3 Interventional

A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes

NCT00330473
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Huntington Beach, California • Pomona, California • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients

NCT00751114
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Sitagliptin, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 70 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 1 Interventional

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02009488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Diego, La Jolla, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

Dexcom G6 Observational Study

NCT03832907
View directory record Official record
Conditions
Diabetes
Interventions
Dexcom G6 CGM - Continues Glucose Monitoring sensor system, POC BG - Point-of-Care Blood Glucose monitoring
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Not applicable Interventional

Examining The Role of CGM in T2DM

NCT01614262
View directory record Official record
Conditions
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions
Continuous Glucose Monitoring with treatment algorithm
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Not applicable Interventional

Glooko mHealth Advantage Study

NCT02974816
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glooko's mobile application
Device
Lead sponsor
Glooko
Industry
Eligibility
18 Years to 75 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Concord, California • Elk Grove, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes

NCT01474018
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
QR-bromocriptine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

NCT01392573
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
58
States / cities
Huntsville, Alabama • Vestavia Hills, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 16, 2026, 10:14 PM EDT
Terminated Not applicable Interventional Results available

Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients

NCT03067480
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus), Continuous Glucose Monitoring
Interventions
iPro2 Professional CGM
Device
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

NCT00972283
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
66
States / cities
Alexander City, Alabama • Birmingham, Alabama • Goodyear, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

NCT00039026
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
126
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430
View directory record Official record
Conditions
End-Stage Renal Disease, Type 2 Diabetes
Interventions
Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 16, 2026, 10:14 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT04460885
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
97
States / cities
Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 85 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 16, 2026, 10:14 PM EDT